DiscoverNew Scientist Colab PodcastsTransforming clinical trials: We meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program
Transforming clinical trials: We meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program

Transforming clinical trials: We meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program

Update: 2024-02-28
Share

Description

As the UK transforms its ecosystem for clinical trials, the regulatory landscape is undergoing its biggest change in 20 years. In this third episode of this free New Scientist podcast, we meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program.

 

Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency


Hosted on Acast. See acast.com/privacy for more information.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Comments 
loading
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Transforming clinical trials: We meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program

Transforming clinical trials: We meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program

DMG Media